Skip to content

Change in AP at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$1.8M+52.4%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$1.34M-29.4%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$2.31M+1,146%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$6.53M-37.1%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$7.91M+358%
LBR
LB Pharmaceuticals Inc Common StockLBRX
$3.46M+220%

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$887.88M+1,358%
Enterprise value$644.49M-958%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alto Neuroscience's change in AP?
Alto Neuroscience (ANRO) reported change in AP of $1.49M in Q1 2026.
How has Alto Neuroscience's change in AP changed year-over-year?
Alto Neuroscience's change in AP increased by 660.2% year-over-year, from -$266K to $1.49M.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.